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ABSTRACT
Objective: To evaluate the response to CPAP in patients with chronic insomnia disorder (CID) 
with OSAS in an unselected patient population including all OSAS severity groups. As a second-
ary objective, we also wanted to evaluate the differences between patients that improve insomnia 
symptoms with CPAP and patients that do not improve, specifically evaluating possible gender dif-
ferences. Methods: Retrospective study of  patients with a diagnosis of  OSAS treated with CPAP 
and CID at the first clinical visit, selected from a database of  an outpatient sleep clinic of  University 
Hospital. Results: From a database of  total of  827 patient, 90 patients were identified with OSAS 
and CID (53.3% women). Middle / moderate OSAS was diagnosed in 68.9% and severe OSA in 
31.1%. Most patients (61.1%) improved insomnia symptoms after CPAP therapy. In the responders 
group, 58.2% had initial insomnia, 63.6% middle insomnia and 12.7% late insomnia.  Responders 
to CPAP were more frequently women (women 61.8%, men 38.2%, p = 0.035) and there was no 
other difference between responders and non-responders. On subgroup analysis, this difference 
was significant only in severe OSAS (women 88.9%, men 31.6%, p = 0.013). Conclusion: In most 
patients with CID and OSA, there is a consistent reduction of  insomnia symptoms with the CPAP 
use. This factor emphasizes the importance of  performing PSG in CID. Insomnia in men with se-
vere OSAS responds less frequently to CPAP suggesting that in these cases the insomnia phenotype 
is less dependent on the respiratory symptoms.
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Chronic insomnia disorder (CID) and obstructive 
sleep apnea syndrome (OSAS) are two common sleep 
disorders which frequently co-occur1. Different studies 
documented that 40-60% of  OSAS patients have insomnia 
symptoms, far exceeding the percentage present in the 
general population2,3. Furthermore, 29%-67% of  patients 
with insomnia have an apnoea-hypopnoea index greater than 
5, indicating the presence of  at least a mild degree of  sleep-
disordered breathing4. These two diseases influence each 
other in negative ways leading to greater illness severity5. 
Some studies reveal that patients with OSAS and comorbid 
insomnia have more depression, anxiety and stress-related 
symptoms, comparing with patients with isolated OSAS6. 
Furthermore, OSAS is an established cardiovascular risk 
factor7 and there is increasing evidences for similar adverse 
effects in CID8.
Theoretically, the impact OSA treatment in patients with 
CID may have contradictory results. On the one hand, the most 
commonly used treatment for OSA is a continuous positive 
airway pressure (CPAP)9. Some studies suggest that the co-
occurrence of  OSAS and insomnia symptoms may complicate 
OSAS treatment and reduce CPAP adherence, leading to 
increased sleep difficulties10,11, especially in patient with sleep-
onset insomnia2. One the other hand, suppressing abnormal 
respiratory events may reduce frequent awakenings, which may 
lead to insomnia improvement.
Despite the aforementioned common co-occurrence 
of  OSAS and CID and its cumulative impact on patient’s 
health, few studies have analyzed the impact of  OSAS 
treatment in insomnia symptoms. Earlier studies using 
small patient groups have suggested that, in mild OSAS, 
the combined treatment of  insomnia with cognitive-
behavioral therapy and OSAS treatment with different but 
predominantly surgical modalities was superior to isolated 
insomnia treatment12-14.
More recent case series showed significant 
improvement in insomnia symptoms in OSAS patients 
when treated with CPAP2,15-17. However, these studies 
analyzed mostly patients with severe OSAS diagnosed with 
ambulatory cardiorespiratory recordings12 or patients without 
comorbidities like anxiety17. Furthermore there is evidence to 
support that man and women have different OSAS related 
symptoms18 and different clinical profiles when OSAS is 
comorbid with insomnia19. None of  the previous studies 
has specifically analyzed differences in insomnia symptoms 
response to CPAP treatment in men and women.
We have, therefore, aimed at evaluating the response to 
CPAP in patients with CID with OSAS in an unselected patient 
population including all OSAS severity groups. As a secondary 
objective, we also wanted to evaluate the differences between 
patients that improve insomnia symptoms with CPAP and 
patients that do not improve, specifically evaluating possible 
gender differences.
METHODS
The study is a retrospective case series. Patients were 
selected from a database of  an outpatient sleep clinic of  
University Hospital - Hospital de Santa Maria, Centro Hospitalar 
Lisboa Norte. All patients with a diagnosis of  OSAS treated with 
CPAP and CID at the first clinical visit were included. Patients 
without clinical follow-up or with insomnia that developed 
after CPAP use were excluded. OSAS and CID were diagnosed 
clinically by a sleep disorders specialist.
OSAS was considered when there is five or more 
predominantly obstructive respiratory events per hour 
of  sleep during PSG plus signs/symptoms (associated 
sleepiness, fatigue, insomnia, snoring, subjective nocturnal 
respiratory disturbance, or observed apnea) or associated 
medial or phychiatric disorder (hypertension, coronary artery 
disease, atrial fibrillation, congestive heart failure, stroke, 
diabetes, cognitive dysfunction or mood disorder), according 
to ICSD-3 criteria.
OSAS severity was classified as mild/ moderate when 
the RDI was between 5-30/h and severe when the RDI was 
≥ 30/h. Hypopneas were classified when there was a > 30% 
reduction of  nasal flow associated with 3% desaturation or 
microarousal, according to the most recent AASM criteria20. 
Questions regarding sleep quality were also evaluated through a 
structured questionnaire that is applied to all patient on the first 
clinical visit. The main outcome was insomnia improvement 
after CPAP use, based in clinical impression by a sleep specialist, 
as recorded in the patient clinical file, from 1 to 12 months 
after CPAP start. CPAP responder was considered when the 
patients improved insomnia after initiating CPAP. Given the 
retrospective nature of  the study, the periodicity of  the clinical 
visit was variable. However, as a general rule in our sleep clinic, 
patients are evaluated 1 month, 3 months and 12 months after 
starting CPAP.
Other variables analyzed were age, sex, body mass index 
(BMI), presence of  vascular risk factors, presence of  anxiety/
depressive symptoms, use of  sedative/hypnotic treatment before 
CPAP use, Apnea hypopnea index (AIH), Respiratory distress 
index (RDI), Epworth sleepiness scale (ESS), CPAP compliance, 
sedative/hypnotics  after the CPAP use, OSAS severity and type 
of  insomnia (initial, maintenance, terminal). CPAP compliance 
was considered when there was > 75% of  use during > 4hours.
Statistical analysis included descriptive statistics and 
comparisons between responders and non-responders to CPAP 
made with T test in continuous variables, Qui2 or Fischer exact 
test in categorical variables (p < 0.05).
RESULTS
From 827 patients, 95 patients had OSAS and CID in the 
first clinical evaluation. Five patients were excluded because they 
did not have follow up information regarding insomnia evolution 
after CPAP use. Therefore 90 patients were evaluated in this 
study (Figure 1). Table 1 documents the clinical characteristics 
of  the patients, based on questionnaire responses.
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All (n=90)
Do you have problems in fall asleep? Yes 59.0%
Do you awake up during night? Yes 98.8%
How many times do you wake up during 
night? 3.35±1.457
How long do you stay awake? 3.99±2.471
Have you been sleepy?  Yes 54.2%
Have you been tiredness?  Yes 75%
Do you have sleep or tired problems in your 
work?  Yes 48.2%
How often do sleep problems arise?
Continuously 52.2 
%, Sporadically 
6.7%; Often 36.7%; 
Periodically 4.4%




Age Mean 62.06±11.64; Median 64.00
BMI Mean 28.68±4.88; Median 27.74
Vascular risk factors Yes 57.8%
Anxiety/ depressive symptoms 
(n=83)  Yes 36.1%
Use of  the sedative therapeutic before 
the CPAP use Yes 55.6%
AHI Mean 23.75±18.99; Median 17.0
RDI Mean 24.95±13.93; Median 21.0
ESS Mean 8.80±5.26; Median 8.00
CPAP compliance Yes 78.9%
Sedative therapeutic after CPAP 
beginning (n=85) Yes 35.3%
BMI- body mass index, AHI- apnea hypopnea index; RDI- respiratory disturb index; 
ESS- Epworth sleepiness scale;
Age, BMI, AHI, RDI, ESS: mean ±SD.
Table 2. Baseline characteristics.
Figure 1. Flow chart of  the participants.
The baseline characteristics are presented in Table 2. 
From the 90 patients with OSAS and insomnia, 53.3% were 
females. The mean age was 62.1±11.64 years. Most patients 
were obese (mean BMI 28.68±4.9 kg/m2). Before starting 
CPAP, 55.6% of  patients were on sedative/hypnotic drugs 
and 36.1% had anxiety/depressive symptoms. Around two 
thirds (68,9%) had mild/moderate sleep apnea (mean AHI 
23.75±18.99; RDI 24.95±13.9). Most patients were not sleepy 
(mean ESS 8.80±5.26).
The Figure 2 shows the baseline prevalence of  insomnia 
symptoms among all patients. The most common insomnia 
subtype was intermediate insomnia, but initial and terminal 
insomnia were also present. It is important reinforce that 
there were also patients with concomitant initial and middle 
insomnia (22.2%), middle and late insomnia (4.4%), initial 
and late insomnia (1.1%) and also patients that complained 
of  the three insomnia subtypes (3.3%) (Figure 2).
Most patients (78.9%) were compliant with CPAP. One 
third of  the patients (35.3%) had to start hypnotic/sedative 
treatment after CPAP. Most of  this treatment was introduced 
to increase CPAP compliance (67.9%) or depressive/anxiety 
symptoms (21.5%). Only 10.7% of  the patients started 
pharmacological treatment specifically to decrease insomnia 
symptoms. This treatment was transient in 20% of  these 
patients, having been discontinued at 12 months follow-up.
Insomnia symptoms improved in 61.1% for the patients 
after CPAP use. This was noted, on average, 5.35±4 months 
after CPAP use. From these patients, 58.2% had initial insomnia, 
63.6% middle insomnia and 12.7% late insomnia.
Figure 2. Baseline prevalence of  insomnia symptoms among all patients.
Table 3 describes the differences between responders 
and non-responders to CPAP. Responders were more 
frequently women (p value=0.035). We did not find any other 
difference between these two groups. Improvement after 
CPAP was similar in men and women with mild/moderate 
OSA. However, men with severe OSA were less likely to 
improve insomnia symptoms (31.6%) that women (88.9%) 
after CPAP (Table 4).
In Supplementary material, the baseline characteristics 
of  men and women from our sample are described.  The only 
significant difference was a higher percentage of  women 





Responders (n = 55) Non- responders (n=35) p Value
Age 62.78±10.70 60.91±13.07 0.461
Sex Fem 61.8%; Male 38.2% Fem 40%; Male 60% 0.035
BMI 28.85±4.68 28.45±5.20 0.724
Vascular risk factors Yes 40.0% Yes 54.3% 0.593
Anxiety/ depressive symptoms Yes 38.5% Yes 32.3% 0.569
AHI 22.02±16.78 26.48±22.00 0.280
RDI 22.61±12.15 26.17±16.51 0.349
OSAS type Mid/Mod 74.6%; Severe 25.4% Mid/Mod 60.0% Severe 40.0% 0.167
Initial insomnia Yes 58.2% Yes 48.6% 0.394
Middle insomnia Yes 63.6% Yes 71.4% 0.298
Late insomnia Yes 12.7% Yes 20.0% 0.262
CPAP compliance Yes 76.4% Yes 82.9% 0.611
Sedative therapeutic after CPAP Yes 34.0% Yes 31.1% 0.471






Women n=8, 88.9% n=1, 11.1%







Women n=26, 66.7% n=13, 33.3%
Men n=15, 65.2% n=8, 34.8%
Table 4. Difference by sex in insomnia improvement after the CPAP use, 
according the OSAS type. 
DISCUSSION
The population of  this study was evaluated 
retrospectively, considering a target population with OSAS and 
insomnia which started CPAP. We analyzed the occurrence of  
insomnia improvement in the first 12 months after beginning 
CPAP. Our results suggest that CPAP has a positive effect in 
insomnia improvement. From the 90 patients, 61.1% improved 
insomnia with CPAP use. This percentage of  response is similar 
to other studies2,15-17. Our data shows that even insomniac 
patients with mild/moderate sleep apnea may respond to CPAP 
treatment and this response is independent on the presence of  
previous psychiatric disorders.
In our study, insomnia subtypes were not associated 
with different treatments responses. Our sample included few 
patients with isolated terminal insomnia, rendering this patient 
group less amenable to conclusions. However, we had one third 
of  patients with isolated sleep-onset insomnia. In this group, 
58% showed improvement after CPAP, a percentage similar to 
patients with sleep-maintenance insomnia (68%). The study by 
Björnsdóttir et al.2 has suggested that only patients with sleep-
maintenance insomnia improve after CPAP. In their study, 
patients with initial insomnia were uncommon (only 3% of  the 
entire insomniac patients) probably due to the way patients were 
selected, from a cohort of  OSAS patients.
We included in our sample all patients referred to the sleep 
clinic, regardless of  the reason of  referral, as long as on the first 
clinical interview CID was diagnosed and OSAS was diagnosed 
on a PSG. They suggest that middle insomnia improves after 
CPAP because there are less OSAS related awakenings. However, 
there is another mechanism by which OSAS treatment may lead 
to insomnia improvement. Reducing symptoms of  un-refreshed 
sleep with CPAP treatment in OSAS reduces the negative impact 
of  bad sleep on daytime functioning and may lead to less sleep-
related effort. This mechanism is of  foremost importance in all 
cognitive-behavioral programs for insomnia21.
The most striking finding in our study is related to the 
gender differences in insomnia response to CPAP treatment. In 
our cohort, women with insomnia and OSAS were more likely 
to improve their insomnia symptoms after CPAP, particularly 
so in the severe OSAS group. There are few studies that have 
specifically looked from different treatment responses in men 
and women with OSA. It is noteworthy that the only difference 
between men and women was higher frequency of  depressive 
symptoms in women. Factors that might be related to this 
different response, like OSAS severity, CPAP compliance and 
insomnia subtypes were similar in both groups.
There are very few studies that evaluate sex differences 
comorbid OSAS and insomnia. One study showed that gender 
differences in these two pathologies could be partially explained 
by different sleep architectures between men and women. 
Men with OSAS-insomnia had decreased sleep efficiency and 
increased sleep latency comparing to men with OSAS-alone. 
In contrast, PSG based sleep architecture was not different 
between women with OSAS-insomnia and OSA alone22.
Insomnia is a much more common manifestation of  
OSAS in women than in men23. It is possible to hypothesize 
that for men with OSAS to develop insomnia, the relative 
importance of  other insomnia related-factors, namely genetic, 
environmental, behavioral or physiological19 has to be bigger 
than in women. This group of  patients may require more 
specific insomnia related interventions.
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It is important to acknowledge that 38.9% of  the patients 
did not improve insomnia with CPAP therapy despite having a 
good CPAP compliance. Insomnia is a multifactorial disorder 
and there are other mechanisms related to insomnia which do 
not depend from respiratory sleep disturbance. Recent reports 
have shown that insomnia patients may be divided in different 
phenotypes, related mostly to personality, mood and well-being 
and psychological reactions to insomnia or life events24.
The response to CPAP therapy may different in this 
various insomnia phenotypes but further studies specifically 
designed to evaluate different insomnia subtypes are necessary 
to confirm this hypothesis. As previously analyzed in small 
clinical trials and case series4,13 the best treatment approach 
to patients with comorbid CID and OSAS is combined OSA 
treatment and cognitive behavioral therapy. These small studies 
suggest that this combined approach is better than each isolated 
treatment per se.
Another important clinical finding from our study is the 
high percentage of  compliance to CPAP in patients with OSAS 
and insomnia. Despite initial studies that suggested that this 
group of  patients might have difficulties with CPAP therapy25 
other authors have also shown that CPAP compliance is not 
influenced by comorbid insomnia, with CPAP use per night 
ranges from  6.2 to 3.4 hours26,27.
We acknowledge that this study has important limitations. 
First, it is a retrospective study, carried out on patients followed 
on usual clinical practice. None of  the patients entered a specific 
cognitive –behavioral therapy program for insomnia (CBTi). 
However, the clinicians following all patients had expertise in 
sleep medicine and techniques of  CBTi, which were most likely 
used in each clinical visit. The effect of  this cannot be evaluated 
in our study design28. Secondly, one third of  the patients 
started sedative therapy after the onset of  CPAP, which may 
have contributed to the final result. This variable had not been 
previously evaluated2,15-17.
Nonetheless, all these patients had chronic insomnia 
and were previously refractory to these treatments (55.6% did 
sedative therapeutic before the PAP use) and the percentage 
of  sedative treatment initiation was not different between 
responders and non-responders. Furthermore, 60.0% of  the 
patients that did not change treatment also showed improvement. 
It is also noteworthy that CPAP compliance information was 
evaluated based on clinical impression and no quantitative 
adherence values were included in our analysis. However, this 
clinical impression is always based on automated CPAP reports. 
Lastly, insomnia improvement after the CPAP use was 
evaluated through clinical impression. Validated insomnia 
questionnaires are not used routinely in our sleep clinic, so 
this data was not available. It was not possible also to establish 
which insomnia symptoms, in patients with concomitant initial, 
middle or terminal insomnia improved mostly. Nonetheless, we 
consider that the information derived from the clinician opinion 
is a good reflection of  the usual clinical practice.
To summarize, our results show that in most 
patients with CID and OSA, there is a consistent reduction 
of  insomnia symptoms with the CPAP use. This factor 
emphasizes the importance of  performing PSG in CID, 
as recently suggested in European guidelines for insomnia 
management29. Insomnia in men with severe OSAS responds 
less frequently to CPAP suggesting that in these cases the 
insomnia phenotype is less dependent on the respiratory 
symptoms. Further studies are needed to understand and 
confirm this finding and define the best treatment approach 
to this subgroup of  patients.
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